---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002686"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:19:22.794928+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring

## Summary
- Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.
- Completed enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer's; topline data expected H2 2024.
- Plans to initiate first-in-human studies of ATH-1105 for ALS in H1 2024.
- CMO Hans Moebius retired effective Jan 5, 2024; will serve as Senior Scientific Advisor through March 31 transition period.
- Over 60 patients continue fosgonimeton treatment beyond 18 months in open-label extension.

## SEC filing metadata
- accession: 0000950170-24-002686
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/0000950170-24-002686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/atha-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002686
- JSON: https://secwatch.observer/filing/0000950170-24-002686.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002686.txt

## Key facts
- Executive change
  Hans Moebius changed role as Senior Scientific Advisor at LeonaBio, Inc..
  - Role: Senior Scientific Advisor
  source text: Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/0000950170-24-002686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.